



SYNCHROMAX

Noninvasive cardiac electrical synchrony assessment.

Synchromax® is a portable ECG monitor to assess the degree of interventricular asynchrony before, during and after the implant of a pacemaker, an implantable defibrillator or a cardiac resynchronization (CRT) device. The process is done noninvasively and in a few minutes.

It is possible now for the physician or the technician to define if a patient will benefit or not from an implant. Optimal pacing sites can easily be localized during the implant, and the device parameters can be optimally programmed during the follow-up.

The proprietary software generates the necessary reports and stores all the information.



SYNCHROMAX Allows:

- Assessing the basal asynchrony level (CRT candidate?)
- Verifying the pacing site effect on asynchrony, during the implant of pacemakers and resynchronizers (CRT devices)
- Adjusting the CRT device interventricular (V-V) interval to minimize asynchrony.
- Evaluating asynchrony during devices follow-up, optimizing the parameter programming.
- It makes optimal physiological pacing a simple task.

No simple and inexpensive method was available so far for the evaluation of the impact on asynchrony of the chosen pacing site.

Synchromax[®] minimizes the risk of worsening the cardiac asynchrony by wrong pacing site selection.



An easy way to program V-V or A-V interval during follow-up to minimize asynchrony was not possible either. Besides, each patient needs specific programmable parameters, at discharge and during the follow-up.

Synchromax[®] offers a simple and reliable noninvasive method:

- For the prescribing physician, to confirm the presence of asynchrony before indicating a CRT device.
- For the implanting physician, to know the impact of the chosen pacing site on the asynchrony.
- For the physician or technician at discharge, to verify the effect on asynchrony of the different parameters that are being programmed.
- For the prescribing physician, to confirm that the device has improved the asynchrony that motivated the device indication.
- For the implanting physician, allows right ventricular pacing site selection that does not worsen asynchrony.



These objectives are achieved processing the surface ECG signals, showing self-explanatory curves to verify the asynchrony degree and quantifying it through a proprietary CSI (Cardiac Synchrony Index).

Contact: **María Eliana Rappallini** Biomedical Engineer I Medical Technologies Manager

Tel.: (+54 11) 4000-7090 E-mail: eliana@synchromax.com



Provider 2021 and Microsoft® Partner.

